3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity

Patent Citations (22)

Non-Patent Literature (64)

• Galambos, Geza et al, CA 123: 169529, 1995.Applicant
• Andreani, A. et al, CA 117: 26247, 1992.Applicant
• Akbasak and Sunar-Akbasak et al., “Oncogene: cause or consequence in the development of glial tumors,” J. Neuro. Sci., 111:119-133 (1992).Applicant
• Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]Thiazolylmethylene)-2-indolinones,” Eur. J. Med. Chem., 32:919-924 (1997).Applicant
• Arteaga et al., Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest., 84:1418-1423 (1989).Applicant
• Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,” Biochemistry, 33:10450-10456 (1994).Applicant
• Kendall and Thomas, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded Soluble receptor,” Proc. Natl. Acad. Sci., USA 90:10705-10709 (1993).Applicant
• Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in Vivo,” Nature, 362:841-844 (1993).Applicant
• Kinsella et al., “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,” Exp. Cell Research, 199:56-62 (1992).Applicant
• Koch et al, “SH2 and SH3 Domains: Elements that control interactions of cytoplasmic signaling proteins,” Science, 252:666-674 (1991).Applicant
• Komada et al., “The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are Mediated through the cytoplasmic domain of the c-Met receptor,” Oncogene, 8:2381-2390 (1993).Applicant
• Korc et al., “Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated With concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha,” J. Clin. Invest., 90:1352-1360 (1992).Applicant
• Korzeniewski and Callewaert, “An enzyme-release assay for the natural cytotoxicity,” J. Immunol. Methods, 64:313-320 (1983).Applicant
• Kumabe et al., “Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a Portion of the extracellular region in a primary brain tumor of glial origin,” Oncogene, 7:627-633 (1992).Applicant
• Lee and Donoghue, “Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal Transduction,” Journal of Cell Biology, 118:1057-1070 (1992).Applicant
• Soldi et al., “Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion Kinase (p125FAX) in human endothelial cells,” Oncogene, 13(3):515-525 (1996).Applicant
• Tsai et al., “The effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-Indolinone on the Nerve terminal currents of mouse Skeletal muscles,” Neurophamacology, 31(9):943-947 (1992).Applicant
• Zamen et al., “Tyrosine Kinase activity of purified recombinant cytoplasmic domain of Platelet-derived growth Factor β-Receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases,” Biochemical Pharmacology, 57(1):57-64 (1999).Applicant
• Zhang et al., “Microtubule effects of Welwistation, a cyanobacterial indolinone that circumvents multiple drug Resistence,” Molecular Pharmacology, 49:228-294 (1996).Applicant
• Baserga, “The insulin-like Growth Factor I Receptor: A Key to Tumor Growth?,” Cancer Research, 55:249-252 (1995).Applicant
• Baserga, “Oncogenes and the Strategy of Growth Factors,” Cell, 79:927-930 (1994).Applicant
• Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,” FASEB J., 6:3403-3409 (1992).Applicant
• Bolen, “Nonreceptor tyrosine protein kinases,” Oncogene, 8:2025-2031 (1993).Applicant
• Bonner et al., “Structure and Biological Activity of Human Homologs of the raf/mil Oncogene,” Molecular and Cellular Biology, 5:1400-1407 (1985).Applicant
• Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,” Int. J. Cancer, 54:571-577, (1993).Applicant
• Coppola et al., “A functional Insulin-Like Growth Factor I Receptor required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,” Molecular and Cellular Biology, 14:4588-4595 (1994).Applicant
• Decker and Lohmann-Matthes, “A quick and simple method for the quantitation of lactate dehydrogenase Release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) Activity,” J. Immunol. Methods, 15:61-69 (1988).Applicant
• Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,” Cancer Treatment Res., 61:249-273 (1992).Applicant
• Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signal Pathways,” Cell, 69:413-423 (1992).Applicant
• Fendly et al., “Characterization of Murine Monoclonal Antibodies Reactive to either the Human Epidermal Growth Factor Receptor or HER2Ineu Gene Product,” Cancer Research, 50:1550-1558, (1990).Applicant
• Fingl and Woodbury, “Chapter 1—General Principles”, In the Pharmacological Basis of Therapeutics, 5th ed. Goodman and Gilman editors, MacMillan Publishing Co., Inc. New York, pp. 1-46 (1975).Applicant
• Floege et al., “Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,” Kidney Internaitonal, 43:S47-S54, (1993).Applicant
• Goldring and Goldring, “Cytokines and Cell Growth Control,” Critical Reviews in Eukaryotic Gene Expression, 1:301-326 (1991).Applicant
• Honegger et al., “Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,” Cell, 51:199-209 (1987).Applicant
• Tuzi et al., “Expression of growth factor receptors in human brain tumors,” Br. J. Cancer, 63:227-233 (1991).Applicant
• Voller et al., “Ch. 45—Enzyme-linked immunosorbent assay,” Manual of clinical immunology 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C. pp. 359-371 (1980).Applicant
• Wright et al., “Inhibition of angiogenesis in Vitro in Ovo with an inhibitor of cellular protein kinases, MDL 27032,” J. Cellular Physiology, 152:448-457 (1992).Applicant
• Andreani et al., “In vivo cardiotonic activity of prridylmethylene-2-indolinones,” Arzneimittel-Forschung Drug Research, 48(II):727-729 (1998).Applicant
• Carpenedo et al, “Indentification and measurement of oxindole (2-indolinone) in the Mammalian brain and Other rat organs,” Analytical biochemistry, 244:74-79 (1997).Applicant
• Chen et al., “Effects of 3,3-Dipyridylmethyl-1-phenyl-2-indolinone on γ-Aminobutyric acid elicited chloride current of snail central neuron,” Chinese Journal of Physiology, 40(3):149-156 (1997).Applicant
• Damiani et al., “Inhibition of Cooper-Mediated low density lipoprotein peroxidation by Quinoline and Indolinone Nitroxide radicals,” Biochemical Pharmacology, 4896:1155-1161 (1994).Applicant
• Davis et al., “Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and related Compounds,” Journal of Medicinal Chemistry, 16(9):1043-1045 (1973).Applicant
• Graziani er al., “Hepatocyte growth factor/scatter factor stimulates the Ras-Guanine Nucleotide Exchanger*,” The Journal of Biological Chemistry, 268(13):9165-9168 (1993).Applicant
• Kato et al., “Simutaneous determination of Amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in Human plasma by high-performance liquid chromatography,” J. of Chromatography, 616:67-71 (1993).Applicant
• Maass et al., “Viral resistance to the Thiazolo-Iso-Indolinones, a new class of nonnucleoside inhibitors of Human immunodeficiency virus type 1 reverse transcrptase,” Antimicrobial agents and chemotherapy, 37(12):2612-2617 (1993).Applicant
• Moreto et al., “3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the active metabolite of the laxative Sulisatin,” Arzneimittel-Forschung Drug Research, 29(II):1561-1564 (1979).Applicant
• Moreto et al., “Study of the laxative properties of the disodium salt of the sulfuric diester of 3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (Dan-603) in the Rat,” European J. of Pharmacology, 36:221-226 (1976).Applicant
• Singh et al., “Indolinone derivatives as potential antimicrobial agents,” Zentralbl. Mikrobiol, 144:105-109 (1989).Applicant
• Singh et al., “Synthesis and anticonvulsant activity of new 1-Substituted 1′-Methyl-3-Chloro-2-Oxosprio (Azetidin-3′, 4-Indol-2′ Ones),” Bollettino Chimico Farmaceutico, 133:76-79 (1994).Applicant
• Macauley er al., “Autocrine function for insulin-like growth factor I inhuman small cell lung cancer cell lines and Fresh tumor cells,” Cancer Research,50:2511-2517 (1990).Applicant
• Mariani et al., “Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor,” Experimental Therapeutics—Proceedings of the American Association for Cancer Research, 35:381 at Abstract No. 2268 (1994).Applicant
• Morrison et al., “Signal Transduction from Membrane to Cytoplasm: Growth factors and membrane-bound Oncogene products increase Raf-1 Phosphorylation and Associated protein kinase activity,” Proc. Natl. Acad., Sci USA, 85:8855-8859 (1988).Applicant
• Mosmann, “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and Cytotoxicity assays,” J. Immunol. Methods, 65:55-63 (1983).Applicant
• Plowman et al., “Receptor tyrosine kinases as targets for drug intervention,” DN&P, 7(6):334-339 (1994).Applicant
• Rygaard and Povisen, “Heterotransplantation of a human malignant tumour to ‘Nude’ Mice,” Acta path. Microbiol. Scand., 77:758-760 (1969).Applicant
• Sandberg-Nordqvist et al., “Characterization of insulin-like growth factor 1 in human primary brain tumors,” Cancer Research, 53:2475-2478 (1993).Applicant
• Schlessinger and Ullrich, “Growth factor signalling by receptor tyrosine kinases”, Neuron, 9:383-391 (1992).Applicant
• Slamon et al., “Studies of the HER-2Ineu Proto-oncogene in human breast and ovarian cancer,” Science, 244:707-712 (1989).Applicant
• Songyang et al., “SH2 domains recognize specific phosphopeptide sequences,” Cell, 72:767-778 (1993).Applicant
• Songyang et al., “Specific Motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav,” Molecular and Cellular Biology, 14:2777-2785 (1994).Applicant
• Superti-Furga et al., “A functional screen in yeast for regulators and antagonizers of heterologous protein Tyrosine kinases,” Nature Biotech, 14:600-605 (1996).Applicant
• Superti-furga et al., “Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src,” EMBO J., 12:2625-2634 (1993).Applicant
• Takano et al., “Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C,” Mol. Bio. Cell, 4:358A at abstract No. 2076 (1993).Applicant
• Torp et al., “Expression of the epidermal growth factor receptor gene in human brain metastases,” AMPIS, 100:713-719 (1992).Applicant